BioRestorative Therapies, Inc. ("BRT" or the "Company")
(OTCBB:BRTX), a life sciences company focused on adult stem
cell-based therapies for various personal medical applications, today
announced that it has entered into a Research and Development Agreement
(“Agreement”) with Rohto Pharmaceutical Company, Ltd. (“Rohto”). Under
the Agreement, BRT has been engaged to provide stem cell research and
development services.
Rohto is a Japanese global pharmaceutical company with approximately
$1.3 billion in sales that develops new technology for the medical and
cosmetics markets.
“BioRestorative Therapies has expertise in cell biology with
considerable skills in culturing stem cells, and we are delighted that
Rohto has selected BRT to assist it with its cell based therapeutic
program,” said Mark Weinreb, Chief Executive Officer of BRT. “We look
forward to a productive relationship with this new prestigious partner."
About
Rohto Pharmaceutical Company, Ltd.
Founded in 1899, Rohto
Pharmaceutical is the second-largest consumer health company in
Japan, and is a world leader in the manufacturing and marketing of
pharmaceuticals, cosmetics, and skincare and healthcare products. Rohto
has global operations and its products are available in more than 150
countries.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com)
develops products and medical procedures using cell and tissue
protocols, primarily involving adult stem cells, including:
-
brtxDISC™ (Disc Implanted Stem Cells)
is an investigational non-surgical treatment for protruding, bulging
and herniated lumbar discs that is intended for patients who have
failed non-invasive procedures and face the prospect of surgery. The
treatment involves culturing a patient’s own stem cells and then
delivering them via a proprietary medical device to the damaged region
of the disc in an outpatient procedure.
-
ThermoStem® is a treatment using brown fat stem cells that is
under development for metabolic disorders including diabetes and
obesity. Initial preclinical research indicates that increased amounts
of brown fat in the body may be responsible for additional caloric
burning as well as reduced glucose and lipid levels.
-
brtx-C Cosmetic is based on the development of a human cellular
extract that has been demonstrated in in vitro skin studies to
increase the production of collagen and fibronectin, which are
proteins that are essential to combating the aging of skin. Potential
cosmetic uses are being explored with third parties.
The Company also offers plant stem cell-based facial creams and beauty
products under the Stem Pearls® brand at www.stempearls.com.
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the Company's Form 10-K filed with the Securities and
Exchange Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance
on such statements. The forward-looking statements in this release are
made as of the date hereof and the Company undertakes no obligation to
update such statements.
Copyright Business Wire 2014